Spruce Street Capital LP
NEW YORK, NY
$510m in 30 US stocks at the end of 30 June 2026. The top 10 are 70.2% of the money. It changed about 16.7% of the portfolio this quarter.
Value
$510m
Stocks
30
Top 10 share
70.2%
Turnover
16.7%
What changed this quarter
New
Bought for the first time this quarter.
- InflaRxIFRX2.4% of the fund
- Research Alliance Corp IIIRACC1.0% of the fund
- ZAI LABZLAB1.0% of the fund
- Achieve Life SciencesACHV0.9% of the fund
- JATT II AcquisitionJATT0.4% of the fund
Added
Bought more of a stock they already held.
- Kiniksa Pharmaceuticals InternationalKNSA11.5% of the fund+21%
- Relmada TherapeuticsRLMD8.7% of the fund+2%
- Alto NeuroscienceANRO7.0% of the fund+2%
- Alkermes plc.ALKS5.6% of the fund+71%
- SavaraSVRA4.2% of the fund+2%
- VaxcytePCVX3.5% of the fund+25%
- Enanta PharmaceuticalsENTA3.1% of the fund+17%
- Perspective TherapeuticsCATX2.5% of the fund+41%
Cut
Sold some of their stake.
- Dianthus TherapeuticsDNTH6.8% of the fund-5%
Sold out
Sold their entire stake.
- Centessa Pharmaceuticals-100%
- Kalvista Pharmaceuticals-100%
- Maze TherapeuticsMAZE-100%
Holdings
- Research Alliance Corp IIIRACC
- Share
- 1.0%
- Value
- $5m
- Shares
- 500,000
New
- Helix Acquisition Corp. IIIHLXC
- Share
- 1.0%
- Value
- $5m
- Shares
- 500,000
Held
- ZAI LABZLAB
- Share
- 1.0%
- Value
- $5m
- Shares
- 279,110
New
- JATT II AcquisitionJATT
- Share
- 0.4%
- Value
- $2m
- Shares
- 160,000
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Kiniksa Pharmaceuticals InternationalKNSA | 11.5% | $59m | 918,070 | +21% |
| Relay TherapeuticsRLAY | 11.0% | $56m | 2,984,125 | Held |
| LB PharmaceuticalsLBRX | 8.8% | $45m | 1,376,159 | Held |
| Relmada TherapeuticsRLMD | 8.7% | $44m | 6,391,328 | +2% |
| Alto NeuroscienceANRO | 7.0% | $36m | 1,353,047 | +2% |
| Dianthus TherapeuticsDNTH | 6.8% | $35m | 354,816 | -5% |
| Alkermes plc.ALKS | 5.6% | $28m | 543,876 | +71% |
| SavaraSVRA | 4.2% | $21m | 3,452,576 | +2% |
| VaxcytePCVX | 3.5% | $18m | 306,047 | +25% |
| Enliven TherapeuticsELVN | 3.3% | $17m | 329,006 | Held |
| Enanta PharmaceuticalsENTA | 3.1% | $16m | 1,088,731 | +17% |
| Perspective TherapeuticsCATX | 2.5% | $13m | 3,693,931 | +41% |
| InflaRxIFRX | 2.4% | $12m | 5,352,198 | New |
| SurrozenSRZN | 2.2% | $11m | 432,040 | Held |
| AlumisALMS | 2.2% | $11m | 392,574 | Held |
| Century TherapeuticsIPSC | 2.0% | $10m | 4,059,054 | Held |
| Minerva NeurosciencesNERV | 1.8% | $9m | 1,655,500 | Held |
| SAB BiotherapeuticsSABS | 1.7% | $9m | 2,198,502 | Held |
| AN2 TherapeuticsANTX | 1.6% | $8m | 1,661,073 | Held |
| ErascaERAS | 1.5% | $8m | 422,543 | Held |
| Inhibikase TherapeuticsIKT | 1.4% | $7m | 3,581,603 | Held |
| Research Alliance Corp IIIRACC | 1.0% | $5m | 500,000 | New |
| Helix Acquisition Corp. IIIHLXC | 1.0% | $5m | 500,000 | Held |
| ZAI LABZLAB | 1.0% | $5m | 279,110 | New |
| Achieve Life SciencesACHV | 0.9% | $5m | 736,637 | New |
| Lexeo TherapeuticsLXEO | 0.8% | $4m | 928,593 | Held |
| AlectorALEC | 0.8% | $4m | 2,101,068 | Held |
| LeonaBioLONA | 0.7% | $4m | 393,701 | Held |
| Corvus PharmaceuticalsCRVS | 0.7% | $3m | 231,585 | Held |
| JATT II AcquisitionJATT | 0.4% | $2m | 160,000 | New |
Over time and by industry
Value over time
Dec '25
Jun '26
Value is up 68.4% since 31 December 2025.
Where the money is
Health care97.6%
Financial services1.4%
Other1.0%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.